Voclosporin Drug Asset Due Diligence Report 2026

This Voclosporin Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Voclosporin can convert its Non-degrading molecular glue, Synthetic peptide, Cyclic Peptide profile and CaN biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Voclosporin (query alias: voclosporin)
Modality / target	Non-degrading molecular glue, Synthetic peptide, Cyclic Peptide; CaN; CaN inhibitors
Highest global status	Approved
Originator	Aurinia Pharmaceuticals, Inc.
Active developers	Otsuka Pharmaceutical Netherlands B.V., Otsuka Pharmaceutical Co., Ltd., Aurinia Pharmaceuticals, Inc.

The MCP disease footprint includes Lupus Nephritis, Acute rejection of renal transplant. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07611214	Phase 4	Recruiting	150	To assess the efficacy of LUPKYNIS in combination with belimumab, obinutuzumab or anifrolumab at inducing rapid renal response: Proportion of patients with complete renal response at 24 weeks
NCT07225387	Phase 4	Recruiting	30	Primary Outcome Measure: Day 360 (12 Month) Outcome
JPRN-jRCTs041250131	Phase 4	募集中	12	The changes in RNA expression levels before initiation of VCS administration, and at 4 and 12 weeks post-initiation, will be analyzed based on prior studies to evaluate the impact of VCS on immune cells.

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

COMPLETE AND PARTIAL RENAL RESPONSE TO VOCLOSPORIN IN DIFFICULT-TO-TREAT PATIENTS WITH LUPUS NEPHRITIS: DATA FROM THE VORLISS (VOCLOSPORIN IN REAL LIFE SETTING STUDY)

Not Applicable; n=77; evaluation: Positive. Reported fields: CRR = 28.0 % ; -; CRR = 22.0 %

VOCLOSPORIN ASSOCIATED WITH A STATISTICALLY SIGNIFICANT 53% REDUCTION IN RISK OF RENAL-RELATED EVENT OR DEATH: A POST-HOC ANALYSIS OF THE AURORA 1 PHASE 3 STUDY

Phase 3; n=356; evaluation: Positive. Reported fields: CRR(Week 52) = 22.5 % ; CRR(Week 52) = 40.8 %

REAL-WORLD OUTCOMES OF COMBINATION IMMUNOSUPPRESSIVE THERAPY IN LUPUS NEPHRITIS: HIGH RESPONSE RATES AND SIGNIFICANT CORTICOSTEROID REDUCTION

Not Applicable; n=66; evaluation: Positive. Reported fields: CRR = 56.0 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Voclosporin addresses Lupus Nephritis, Acute rejection of renal transplant. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Non-degrading molecular glue, Synthetic peptide, Cyclic Peptide—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 5 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2023-01-01	Swixx and Otsuka expand partnership with Lupkynis® and Abilify®	Approved	Financial terms not disclosed
2020-12-17	Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan	NDA/BLA	US$50.0M upfront; US$50.0M milestones
2012-01-03	Isotechnika Enters Into Development and Commercialization License Agreement With Vifor Pharma	Not disclosed	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Methods for treating lupus nephritis with voclosporin”. The milestone feed surfaced a patent-application signal described as “Process for the controlled synthesis of voclosporin”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO